Reazur Rasul compensation by year
BAXTER INTERNATIONAL Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $800,000 |
| Bonus | $0 |
| Stock awards | $2,953,421 |
| Option awards | $931,507 |
| Non-equity incentive | $488,000 |
| Pension and deferred compensation | $0 |
| All other | $73,286 |
| Total | $5,246,214 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BAXTER INTERNATIONAL INC DEF 14A filed March 23, 2026, accession 0001628280-26-020330, and prior-year filings.
How this page was built: the BAXTER INTERNATIONAL INC filed document, accession 0001628280-26-020330. Every figure is read from that document and cited to the page and table it appears in. Filed March 23, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 57,838 | $1,105,281 | — |
| RSU | 26,555 | $507,458 | — |
| PSU | 26,555 | $507,458 | — |
| PSU | 18,942 | $361,989 | — |
| RSU | 5,507 | $105,229 | — |
| Option | 87,417 | — | $35.44 |
| Option | 21,322 | — | $39.06 |
Per the Outstanding Equity Awards at Fiscal Year-End table in BAXTER INTERNATIONAL INC's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments BAXTER INTERNATIONAL discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $2,400,000 | $0 | $21,000 | $2,944,000 |
| Change in control and involuntary termination | $2,400,000 | $3,364,241 | $24,000 | $6,623,241 |
Per the Potential Payments Upon Termination or Change in Control table in BAXTER INTERNATIONAL INC's FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
BAXTER INTERNATIONAL’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Andrew Hider | President and CEO | $29,805,182 |
| Joel Grade | Former Executive Vice President and CFO | $8,209,568 |
| José Almeida | Former Chair of the Board, President and CEO | $7,666,044 |
| Heather Knight | Former Executive Vice President, COO and Interim Group President, Medical Products & Therapies | $6,074,548 |
| Reazur Rasul · this page | Executive Vice President and Group President, Healthcare Systems & Technologies | $5,246,214 |
| Alok Sonig | Former Executive Vice President and Group President, Pharmaceuticals | $5,239,273 |
| Brent Shafer | Non-Executive Chair and Former Executive Chair and Interim CEO | $3,809,993 |
| David Rosenbloom | Executive Vice President and General Counsel | $3,794,164 |
| Cecilia Soriano | Group President, Infusion Therapies & Technologies and Pharmaceuticals | $2,654,841 |
The full BAXTER INTERNATIONAL compensation record
free company briefThis page is one person within BAXTER INTERNATIONAL's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the BAXTER INTERNATIONAL proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order BAXTER INTERNATIONAL's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BAXTER INTERNATIONAL's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.